DETAILS, FICTION AND PARP-1-IN-3

MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To guage several intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Key trial targets have been To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis patien